GENFIT S.A. ADR/1 EO-25 (F:XUPB) — Market Cap & Net Worth
Market Cap & Net Worth: GENFIT S.A. ADR/1 EO-25 (XUPB)
GENFIT S.A. ADR/1 EO-25 (F:XUPB) has a market capitalization of $200.59 Million (€171.58 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #16635 globally and #1569 in its home market, demonstrating a 9.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENFIT S.A. ADR/1 EO-25's stock price €5.90 by its total outstanding shares 50024749 (50.02 Million).
GENFIT S.A. ADR/1 EO-25 Market Cap History: 2020 to 2026
GENFIT S.A. ADR/1 EO-25's market capitalization history from 2020 to 2026. Data shows growth from $230.43 Million to $345.06 Million (10.56% CAGR).
GENFIT S.A. ADR/1 EO-25 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENFIT S.A. ADR/1 EO-25's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check XUPB stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XUPB by Market Capitalization
Companies near GENFIT S.A. ADR/1 EO-25 in the global market cap rankings as of September 20, 2026.
Key companies related to GENFIT S.A. ADR/1 EO-25 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
GENFIT S.A. ADR/1 EO-25 Historical Marketcap From 2020 to 2026
Between 2020 and today, GENFIT S.A. ADR/1 EO-25's market cap moved from $230.43 Million to $ 345.06 Million, with a yearly change of 10.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €345.06 Million | +16.83% |
| 2025 | €295.35 Million | +49.41% |
| 2024 | €197.68 Million | 0.00% |
| 2023 | €197.68 Million | -14.21% |
| 2022 | €230.43 Million | -8.37% |
| 2021 | €251.48 Million | +9.14% |
| 2020 | €230.43 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GENFIT S.A. ADR/1 EO-25 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $200.59 Million USD |
| MoneyControl | $200.59 Million USD |
| MarketWatch | $200.59 Million USD |
| marketcap.company | $200.59 Million USD |
| Reuters | $200.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENFIT S.A. ADR/1 EO-25
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more